CD80 and neoplasm: Some studies have shown that tumor-initiating stem cells inhibit cytotoxic T cell responses via the surface molecule of CD80, which suggests that tumor-initiating stem cells could be essential to activating immune checkpoint pathways (Miao et al., 2019).